Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURMOUNT-ADOLESCENTS tirzepatide versus placebo in adolescents with obesity or overweight
2023-504413-80-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in obesity and Overweight comparing Tirzepatide once weekly with Placebo once weekly (2 arms). Primary endpoint: Percent Change from Baseline in Body Mass Index. Planned start Dec 2023; status: authorised.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on 2023-504413-80-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504413-80-00.